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Safe and eﬃcient gene delivery vectors will enhance the prospects for
polynucleotide-based therapies. Herein a new approach toward structurally
optimized gene vector design based on the preparation of clickable
poly(allylamino-phosphazene)s that can be converted to several cationic and
anionic derivatives via thiol–ene addition is described. Simultaneous
co-incubation of alkylamine- and alkylcarboxylate-poly(phosphazenes) with
polynucleotide generates binary polyelectrolyte nanoparticles. Screening of a
series of these complexes for transfection in glioblastoma cells shows that the
inclusion of 6-mercaptohexanoic acid substituted poly(phosphazene)s in the
complexes results in six-fold and 19-fold higher luciferase expression in
U87MG cells and GBM1 primary cells, respectively. This eﬀect is attributed to
the speciﬁc ionization properties of these materials that improved polyplex
intracellular traﬃcking. Transfection in 3D-spheroid models and subcutaneous
xenograft U87MG tumors conﬁrms higher transgene expression for the binary
cationic/anionic poly(phosphazene) complexes compared to the related
polycation-pDNA complexes and to PEI-pDNA complexes. The data also
indicate a notable capacity of the mixed complexes to deliver genes to the
inner cores of tumor spheroids. Extension of this approach to siRNA delivery
shows that the mixed poly(phosphazene) complexes can silence DYRK1A, a
gene implicated in glioblastoma initiation and progression, reducing U87MG
cell renewal in vitro and delaying tumor growth in vivo.
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1. Introduction
Therapies based on polynucleotides oﬀer
much promise but require more eﬃcient
and safer gene carriers.[1] While viral-based
gene delivery is the most advanced in
terms of the number of clinical trials,[2]
there are still concerns over the long-term
safety of viral vectors, and many of the
new RNA-based drugs are not easy to in-
tegrate in virus-based delivery constructs.
Non-viral systems such as polymer-based
gene vehicles have provided a number of
promising results, but there remain several
limitations for their generalized appli-
cation.[3] Design criteria that remain unful-
ﬁlled by most synthetic polymer gene carri-
ers include a) biocompatibility and tunable
biodegradability, b) selective biodistribution
and adequate pharmacokinetics, c) ability to
surmount tissue and extracellular barriers,
and d) transport across intracellular barriers
and organelle-speciﬁc release.
Poly(phosphazene)s are a class of bio-
degradable materials that could provide
these urgently needed characteristics to
gene carriers. Pioneering work from the
Allcock group established some of the key
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pharmaceutical parameters for these materials,[4] and recent
studies have shown that poly(phosphazene)s and their variants
can eﬀectively deliver small drug molecules, proteins, and nu-
cleic acids in a number of therapeutic settings.[5] The versa-
tility of poly(phosphazene) chemistry derives from the possi-
bilities to modify a precursor, poly(dichlorophosphazene), by
nucleophilic substitution. However, when preparing polymers
for gene delivery, this synthetic route is problematic because
most functional groups display more than two nucleophilic
centers, which can result in general crosslinking of the ma-
terial during derivatization reactions leading to precipitation
of the partially substituted polymer. Recently, a few strategies
to introduce “click” handles in poly(phosphazene)s have been
reported,[6] which might be used to circumvent this problem.
In this study, we have developed a poly(phosphazene) plat-
form, containing side-chain double-bond repeating units, and
prepared a series of cationic and anionic derivatives of these
via thiol–ene grafting chemistries using α, ω-aminoalkanethiols
and α, ω−carboxylatoalkanethiols. By combining these mate-
rials in the presence of nucleic acids, we aimed to generate
mixed polyelectrolyte complexes with suﬃcient positive charge to
bind polynucleotides and promote cell internalization, but with
the capacity to destabilize cell membranes in response to pH,
and at the same time to minimize polycation-induced toxicity.
These optimized complexes were expected to escape more eﬀec-
tively than conventional polycation/nucleic acid complexes from
the endolysosomal compartment, which has been considered
to be the most signiﬁcant intracellular barrier to eﬀective gene
delivery.[3b,7]
Accordingly, we have applied these gene carriers to deliver
nucleic acids as a potential means to treat glioblastoma (GBM),
which is a highly aggressive and malignant cancer usually clas-
siﬁed as grade IV by the World Health Organization (WHO), in
view of patients’ short median survival time after diagnosis (14
months).[8] While this prognosis has improved slightly by the in-
troduction of the Stupp protocol treatment, that is, radiotherapy
plus temozolomide (TMZ) after surgical resection of diagnosed
tumors,[9] the presence of highly resistant tumor-initiating cells
(TIC) still results in limited treatment options for most patients,
leading to tumor relapse and failure of the therapy. There is
an urgent need for better treatment strategies, and delivery of
either suicide genes or gene knockdown by siRNA are possible
means by which glioblastomas could be eﬀectively targeted. For
example, previous studies have shown that inhibition of dual-
speciﬁcity tyrosine phosphorylation–regulated kinase (DYRK1A)
caused a loss of self-renewal capacity in several primaryGBMTIC
cells through preventing endocytosis-mediated degradation of
epidermal growth factor receptor (EGFR) by the phosphorylation-
requiredmodulator Sprouty2.[10] In addition, advances in surgical
resection for GBM-diagnosed patients are allowing for promising
strategies for in situ post-operative administration, for example,
the introduction of sustained-releasewafers to release anti-cancer
agents in situ.[11] In this work, we applied the poly(phosphazene)
platform to deliver siRNA against DYRK1A to GBM tumors
via intratumor administration and report a ﬁrst proof of ther-
apeutic eﬃcacy in vivo in combination with an anti-neoplastic
treatment.
2. Experimental Section
2.1. Materials
Hexachlorocyclotriphosphazene (99%), aluminum chloride
(99.99%), triethylamine (TEA), cysteamine, 2-(dimethylamino)
ethanethiol hydrochloride (DMAES), 2,2-dimethoxy-2-
phenylacetophenone (DMPA), branched poly(ethyleneimine)
Mw 25K (PEI), 3-mercaptopropionic acid (3MPA), 4-
mercaptobutyric acid (4MBA), 6-mercaptohexanoic acid
(6MHA), 8-mercaptooctanoic acid (8MOA), heparin sodium salt
(from porcine intestinal mucosa), anhydrous tetrahydrofuran
(THF), 2,2,2-triﬂuoroethanol (TFE), anhydrous diethylene glycol
dimethyl ether (Diglyme), ethidium bromide (EtBr), poly-l-lysine
(Mw 30–70 kDa) were all purchased from Sigma-Aldrich and
used as received.
2.2. Synthesis of the Precursor Poly(allylamino-Phosphazene)
Poly(dichlorophosphazene) (PDCP) was prepared as previously
described.[12] A pre-dried ﬂask was loaded with 5.0 g (14.4 mmol)
of hexachlorocyclotriphosphazene and aluminum chloride as a
catalyst at 5–10 wt%. The reactor was ﬁlled with high-purity ni-
trogen and heated to an initial temperature of 240–250 °C. After
the polymerization had proceeded for 3 h, the reactor was cooled
to 120 °C, and 8 mL of diglyme were injected into the reactor
to solubilize the crude product and to minimize cross-linking.[13]
Aluminum chloride was removed by centrifugation (7000 g at
−10 °C). The product identity was conﬁrmed by 31P NMR in a
co-solvent of diglyme/deuterated chloroform (1:3). Subsequent
nucleophilic substitution at the chlorine phosphorus centers[14]
was performed by transferring the product supernatant into a
pre-dried ﬂask containing 50 mL of anhydrous THF, where TEA
and allylamine (both 3 eq. to chlorine) were added. The reaction
was carried out on ice for 24 h, and then, for additional 24 h at
room temperature. For puriﬁcation, the mixture of raw products
was ﬁltered to remove the trimethylamine hydrochloride and the
polymer was precipitated in a co-solvent (THF/water 1:2) ﬁrst
and then in pure water. The precipitated polymer, allylamino-
poly(phosphazene) (AAPPZ), was collected and dried in vacuo
(yield 4.61 g, 68%).
2.3. Synthesis of Cationic and Anionic Poly(Phosphazene)s by
Thiol–Ene Reactions
After synthesis of the precursor AAPPZ, two diﬀerent amine side
chains were introduced to provide cationic functionality, via reac-
tion of the thiols of cysteamine and dimethyl(aminoethanethiol)
with the alkenyl side chains of the polymer. Analogous reactions
to install various carboxylic acid groups were carried out using
3MPA, 4MBA, 6MHA, and 8MOA. First, AAPPZ (100 mg,
1.27 mmol of allyl groups) in 8 mL TFE was mixed with the
designated mercaptoalkylamine or mercaptoalkyl carboxylic acid
(3 eq. to allyl group) and ﬂushed with nitrogen gas before adding
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2,2-dimethoxy-2-phenylacetophenone (0.05 eq. to allyl groups).
The thiol–ene reaction was initiated under UV irradiation (λ
= 365 nm) for 3 h, and then the crude product was directly
dialyzed against ultrapure water (molar mass cut-oﬀ 7 kDa)
until it became a clear solution. The product was recovered as a
powder by freeze-drying. The polymers were analyzed by NMR
and gel permeation chromatography (GPC).
2.4. Formation of Poly(phosphazene)-Based Complexes
A bi-functional plasmid DNA (pDNA) coding for enhanced green
ﬂuorescent protein (eGFP) and luciferase from ﬁreﬂy Photinus
pyralis was used throughout this work. In this pDNA, wild-type
eGFP was modiﬁed to enhance the ﬂuorescence excitation and
emission at 488 nm and 507 nm, respectively. P. pyralis luciferase
was chosen as it emits yellow-green light with maximum at
560 nm across the pH range of 7.5–8.5.
Cationic poly(phosphazene)s with diﬀerent side-chain ratios
of cysteamine and DMAES were dissolved in 10 mm HEPES pH
5.5. The anionic side-chain poly(phosphazene)s were dissolved
in 10 mm HEPES pH 8.2. The pDNA was dissolved in ultrapure
water. Complexation was performed under intense vortex mixing
for 30 s at various ratios between the positively charged amines
of the polymer and the negative-charged phosphates on the
pDNA (N/P ratio). In the case of the mixed cationic and anionic
poly(phosphazene)s, the polycationic PPZ condensed both the
anionic polymers and the pDNA in one step. These polymeric
complexes were characterized by their stoichiometric composi-
tion ratio, in terms of positive amines (N), negative carboxylates
(C) and negative DNA phosphates (P), that is, N/C/P ratio.
2.5. Characterization
2.5.1. NMR
1H and 31P NMR spectra were recorded on Bruker 400
and DRX-500 spectrometers, respectively. 1H diﬀusion-ordered
spectroscopy (1H DOSY) was recorded on Varian Inova 750
(750 MHz). Solvents used were CDCl3, D2O, and MeOD. All
chemical shifts were reported in parts per million (ppm) relative
to tetramethylsilane (TMS) or known solvent peak positions.
2.5.2. GPC
Molar masses of polymers were determined via gel permeation
chromatography using a Shimadzu Prominence UPLC system
ﬁtted with a DGU-20A5 degasser, LC-20AD, CBM-20A LITE sys-
tem controller, SIL-20A autosampler, CTO-20A oven and RID-
10A refractive index detector. Separations were performed on a
series of Aquagel 30-40-50 (300 × 7.8 mm, 5 mm bead size,
Agilent UK) columns ﬁtted with a matching guard column
(50× 7.8 mm). The mobile phase was acidic buﬀer solution (1 m
acetic acid and 0.3 m NaH2PO4) at 1 mLmin−1 ﬂow rate and sep-
arations were performed at 37 °C. Column calibration was per-
formed using poly(2-vinylpyridine) Easi Vials (2 mL) standards
(668 Da–211 kDa, Polymer Standards Service, USA).
2.5.3. Dynamic Light Scattering and Zeta Potential Measurements
Dynamic light scattering and zeta potential measurements were
performed using a Nanosizer ZS instrument (Malvern, UK) at
25 °C, equipped with aHe–Ne laser (λ = 633 nm) with a backscat-
ter angle of 173°. For zeta potential, measurements were per-
formed in 1 mm KCl. Hydrodynamic radii distributions were cal-
culated with Malvern software. From standard auto correlation
functions, diﬀusion coeﬃcients were related to particle hydrody-
namic radius via the Stokes equation
RH = κBT/6πηD (1)
where RH is the hydrodynamic radius, κB is the Boltzmann con-
stant, T is the temperature, and η is the viscosity of the solvent. In
addition, it was assumed that particles were spherical and non-
interacting.
2.5.4. Electron Microscopy
The morphologies of the polymeric complexes were character-
ized by transmission electron microscopy (JEOL JEM-2010) in
negative staining mode using phosphotungstic acid (PTA, 2%
w/v). The complex suspensions (10 µL of solutions at a plasmid
concentration of 62.5 µg mL−1) were dropped onto a TEM grid
(Carbon Film CF400, Electron Microscopy Sciences) and left for
5 min, when the residual sample was blotted away by capillary
forces. Afterward, the PTA solution was added to the grid for
1 min, and then the grids were washed with ultrapure water and
dried under low-pressure prior to TEM imaging.
2.6. Potentiometric Titration and Gel Electrophoresis
The buﬀering capacities of cationic and anionic
poly(phosphazene)s were determined by initial dissolution
of the polymer in Milli-Q water to give a concentration of 50 mm
of side-chain units. The anionic polymer solutions (0.5 mL)
were adjusted to pH 11 with 1 n NaOH and then titrated with
1 n HCl. In between each addition, the polymers were agitated
under vortex for 30 s and allowed to stabilize for another 30 s
prior to pH measurement. For cationic polymers, solutions of
the same concentration were adjusted to pH 2 with 1 n HCl, and
then titrated with 1 n NaOH using the same method used for
the anionic polymers. pKa calculation and protonation degree
(α) versus pH were calculated from the potentiometric titration
curves (more information on the calculations in Supporting
Information).
For estimating the binding eﬃciency of pDNA complexation,
gel electrophoresis was performed using 1% agarose containing
(0.5µgmL−1) EtBr at 110V for 50min. Each samplewas prepared
to a 30 µL volume containing 1 µg plasmid. In heparin displace-
ment tests, each polymer/DNA complex sample was challenged
with diﬀerent mass ratios of heparin to plasmid, using samples
at a ﬁxed volume (30 µL) and incubated for 1 h at 37 °C.
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2.7. Transfection, Cytotoxicity, and Confocal Imaging on 2D
Monolayer
For 2D transfection and cytotoxicity studies, U87MG cells were
cultured in Dulbecco’s Modiﬁed Eagle Medium (DMEM, Sigma)
containing 10% fetal bovine serum, 2mmGlutamine and 100mg
L−1 penicillin-streptomycin and maintained at 37 °C under a 5%
CO2 atmosphere. For 2D culture, the cells were seeded at a den-
sity of 25 000 cells cm−2 in 24-well plates and incubated 24 h prior
to transfection. Then, polymer complexes were added at various
pDNA concentrations in serum-free media (OptiMEM) and in-
cubated for 4 h. The formulations were removed after the incu-
bation, and cells were then cultured with fresh growth medium
for an additional 48 h. Cell transfection was qualitatively assessed
via ﬂuorescencemicroscopy and quantiﬁed with Luciferase assay
kits (from Promega). Cytotoxicity was evaluated by an MTT assay
(Promega). Brieﬂy, the transfected cells were treated with 10 µL
of 12 mmMTT/PBS solution and incubated with 100 µL phenol-
red free media in each well for 4 h. After the supernatant was re-
moved, 50 µL DMSO aliquots were added to the wells, mixed and
incubated for 10 min before quantiﬁcation on a plate reader with
absorbance wavelength set at 540 nm. For intracellular traﬃck-
ing studies, U87MG cells were attached on poly-l-lysine-coated
8µ-slides (Ibidi) and treated with polymeric complexes carrying
Cy5-labeled blank pDNA (prepared by Label IT kit from Mirus)
at the pDNA concentration of 0.3 µg per well for 4 h. Then the
medium was changed to fresh growth medium for further incu-
bation for another 20 h. After this period, treated cells were in-
cubated with 50 nm of LysoTracker Green (Invitrogen) and 5 µg
mL−1 Hoechst 33 342. Finally, confocal images (Leica SP5 X) in
live cells were taken. For tracking intracellular release of pDNA,
CA-PPZ was labeled with cyanine 3 (Cy3) via conjugation with
Cy3-NHS (from GE) and then complexed with 6MHA-PPZ and
Cy5-pDNA, forming Cy3-CA-PPZ/6MHA-PPZ:Cy5-pDNA com-
plexes. The preparation of confocal microscopy samples was by
the same method described above.
2.8. Transfection and Tomographic Scanning in a 3D Spheroid
Model
For establishing 3D spheroids of U87MG cells, ultra-low attach-
ment 96-well round-bottom plates (Corning) were seeded with
250–5000 U87MG cells per well in growth media, utilizing six
replicates for each experimental condition. The plates were cen-
trifuged at 200 rcf for 5min to induce cell accumulation and stim-
ulate spheroid formation. After 3 days, the spheroids were ad-
judged ready for transfection studies. The spheroids were treated
with diﬀerent polymeric complexes and with diﬀerent pDNA
concentrations (2 and 4 µg mL−1) for 16 h in OptiMEM and then
incubated in growth media for another 80 h. GFP expression
in each spheroid was quantiﬁed at 96 h post treatment, via Im-
ageJ (Fiji package) analysis directly using built-in histogram func-
tions (Figure S9, Supporting Information). The volume of the
spheroids was calculated from phase-contrast microscopic im-
ages (Nikon Eclipse Ti) using an ImageJ plugin macro that mea-
sures spheroid area (A) from deﬁned regions of interest (ROI).[15]
Then, the spheroid area was used to determine the radius (R =
[A/π ](1/2)) and calculate the volume assuming that the cell ag-
gregates formed equivalent spheres. To quantify metabolic activ-
ity in the spheroids, a resazurin reduction assay was performed.
Brieﬂy, the spheroids were treated with resazurin (60 µm) in the
growth media and incubated at 37 °C for 4 h. Following that,
the 96-well plate was measured with a FlexStation II plate reader
set at an excitation wavelength of 530 nm and at an emission of
590 nm. The evaluation ofmembrane integrity in the cell was per-
formed using 7AAD (5 µL per well, 50 µgmL−1) and ﬂuorescence
observed in themCherry channel (Ex 560/55 and ﬁlter 630/60) of
the ﬂuorescence microscope.
The quantiﬁcation of ﬂuorescence intensity in the spheroid
model was carried out via selection of ROI and comparing his-
togram curves of ﬂuorescence intensity (FI) for samples and the
non-treated group control (Figure S9, Supporting Information).
GFP-positive counts were recorded when FIs were higher than
the maximum FI of non-treated groups, set as threshold (Equa-
tion (2)). For GFP-gene transferred expression, there is no opti-
mal positive control. For this reason, GFP expression was quanti-
ﬁed via the percentage of GFP positive pixels. There were at least
four replicates in each independent experiment and displayed
data were analyzed using Prism software from four to nine in-
dependent experiments.
GFP positive pixels % =
∑
Pixels (whose FI > threshold)
∑
Pixels (total)
(2)
For 7AAD, the threshold is deﬁned from the mean ﬂuorescent
intensity (Mean FI) in the untreated group as 0% and themean FI
of 0.5% v/v Triton X-100 treated group as 100%. The percentages
of 7AAD signals of treated spheroids are expressed as below.
Mean FI of 7AAD signals =
∑
Pixel × FI
∑
Pixels (total)
(3)
7AAD positive %
= (Mean FI of treated spheroids)−(Mean FI of non-treatment)
(Mean FI of TritonX treatment)−(Mean FI of non-treatment)
(4)
For 3D imaging, spheroid samples were ﬁxed with 4%
paraformaldehyde ﬁrst and their nuclei stained with DAPI. The
ﬁxed spheroids were loaded in appropriate glass capillaries with
1% w/v low-melt agarose. The imaging was performed by ﬂuo-
rescent light sheet microscopy FLSM (Light-sheet Z.1, Zeiss) and
presented in the same ﬂuorescence intensity scale using ImageJ
software.
2.9. GFP/Luciferase Transfection in Xenografted Model
All in vivo experiments were approved by the Research Ethics and
Animal Welfare Committee at the Instituto de Salud Carlos III,
Madrid, (PROEX 224/14) in agreement with the EuropeanUnion
and national directives. A subcutaneous xenograftmodel of GBM
was established as previously described.[16] Brieﬂy, athymic nude
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Foxn1numice were subcutaneously injected with 1 million fresh
U87MG cells in 80 µL cultured media and 20 µL Matrigel (BD),
on both ﬂanks.When tumor sizes reached around 100–150mm3,
polymer complexes with the GFP/Luciferase pDNA (16 µg per
tumor) were injected intratumorally. One week later, before the
mice were sacriﬁced, they were treated with Luciferin 50mg kg−1
by IP injection. The transfected tumors were excised and imaged
by an In Vivo Imaging System (IVIS).
2.10. Down-Regulation Eﬃciency and Clonogenic Assays
Complexes of polymers with siRNA against DYRK1A (siDYR)
(ON-TARGETplus Human DYRK1A, Dharmacon) with siRNA
concentration 1 µg mL−1 were added to U87MG (75K cells per
well) in 12-well plates for 4 h and then maintained in culture
media for 24 h. The silencing eﬃciency following transfection
was then measured by qRT-PCR. The treated cells were col-
lected formRNA extraction byHigh-pure RNA isolation kit (from
Roche) and ﬁnally, mRNAs were trapped by a glass ﬁber ﬂeece
in ﬁlter tubes. After elution of mRNA, the reverse transcription
of 200 ng mRNA was performed by PrimeScript RT kit (from
TaKaRa). The appropriate cDNA was mixed with SYBR-Green
and either primers of DYRK1A (Forward 5′-3′: GCAATTTCCT-
GCTCCTCTTG; Reverse 5′-3′: TTACCCAAGGCTTGTTGTCC)
or primers of HPRT (Forward 5′-3′: TGACACTGGCAAAACAAT-
GCA; Reverse 5′-3′: GGTCCTTTTCACCAGCAAGCT), used as a
reference (housekeeping gene). Gene expression was measured
by quantitative RT-PCR (Lightcycler-480 II, Roche).
For self-renewal assays, the silenced cells were detached and
left in a serum-free medium, Neurobasal (Fisher-Scientiﬁc) sup-
plemented with B27 (1:50), EGF (40 ng mL−1) and FGF (20 ng
mL−1) (Peprotech) for 3 days to form spheroids. Then, the
spheroids were dissociated by Accumax (Millipore) and the
serum-deprived cells were seeded on 96-well plates (250 cells per
well) for 7–10 days in the same serum-free medium. The num-
bers of secondary spheroids formed were counted.
2.11. Combination Treatment of siRNA of DYRK1A and
Temozolomide in Xenograft Models
To investigate the therapeutic eﬀectiveness of DYRK1A-silenced
gene delivery in vivo, a subcutaneous xenograft model was es-
tablished as described above. When tumor sizes reached around
100–150 mm3, the polymeric complexes were injected intratu-
morally with 4 µg siDYR or the same amount of the scrambled
sequence (siCtrl) for each tumor per day, over 4 consecutive days
(total 16 µg siRNA for each tumor, 0.6 mg kg−1).[17] On the same
treatment days, mice from both study arms were also admin-
istered 5 mg kg−1 TMZ by intraperitoneal injection (total dose
20 mg kg−1 each mouse). The tumor sizes were measured by a
caliper and calculated by Volume = W × W × L/2, in which W
represents width and L is length.
2.12. Hemolysis Tests
Rat blood was collected in K2E tubes containing EDTA (BD Vacu-
tainer) and was centrifuged at 1000 rcf for 5 min. After washing
with PBS three times under the same centrifuge conditions, the
red blood cells were re-suspended either in PBS 7.4 or in PBS 5.5
at 3% (w/v) concentration. The erythrocyte suspensions were al-
located across 96 wells and incubated with either CA-PPZ:pDNA
or CA-PPZ/6MHA-PPZ:pDNA complexes for 2 h at 37 °C
under mild shaking. Then, the plates were centrifuged and the
supernatants transferred to a new plate for colorimetric analysis.
The absorption of the released hemoglobin was measured in a
96-well plate reader at an excitation wavelength of 570 nm. The
maximum hemolysis (positive control) was established using
cells treated with 1% (v/v) Triton X-100 and the minimum value
was set by treatment with PBS either at pH 7.4 or at pH 5.5.
2.13. Statistical Analysis
All data were presented as mean ± standard error of the mean
(SEM). For statistical analysis, data were transformed if required
for normalization. The normality of the data was tested by a
Shapiro–Wilk test. Signiﬁcant diﬀerences were tested with Stu-
dent’s t tests or ANOVA. p-Values < 0.05 were considered to be
signiﬁcant, although p-values below this level are also noted in
individual ﬁgures and in the text. Statistical tests applied and
the number of independent replicates are noted in the ﬁgure
captions. All statistical analyses were carried out via GraphPad
Prism 7.
3. Results
The strategy for the synthesis of various substituted
poly(phosphazene)s was via thermal ring-opening polymer-
ization of the cyclic monomer hexachlorophosphazene (1) and
reaction of the resultant PDCP with allylamine under basic
conditions to aﬀord vinylic side chains.[6b] These were amenable
to thiol–ene derivatization to yield a series of polycations and
polyanions (Figure 1a).
The initially formed PDCP (2) was characterized by 31P NMR
(Figure S1, Supporting Information), and this compound was re-
acted by nucleophilic substitution at the P–Cl bonds with ally-
lamine to generate the key precursor polymer AAPPZ. A range
of diﬀerent cationic (4–6) and anionic (7–10) side-chain poly-
mers (Figure 1a) were generated from AAPPZ via thiol–ene click
chemistry. Reactions proceeded to a high degree (93% substi-
tution of the allyl groups by the cationic side chains) and good
overall yield (71%). Product identity was conﬁrmed by 1HNMR
(Figures S2, Supporting Information). The molar masses of the
ﬁnal product cysteamine-linked poly(phosphazene) (CA-PPZ, 4)
were estimated by aqueous GPC, with calibration against com-
mercial standards of poly(2-vinylpyridine). Two families of CA-
PPZ polymers were characterized with molar masses of Mw
35.9 ± 3.9 kDa (PI = 1.54) and 26.0 ± 2.4 kDa (PI = 1.56), re-
spectively.
The polymers were intended as nucleic acid carriers, for
which their abilities to act as “proton-sponges” and/or mem-
brane disruptors[18] are highly dependent on their ability to
accept protons and to change their hydrophilic/ lipophilic
balance across intracellular pH ranges. The apparent pKa values
of the polycations and polyanions were thus determined by
potentiometric titrations (Figure S3, Supporting Information,
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Figure 1. Synthesis and characterization of cationic and anionic poly(phosphazene)s. a) Synthesis of either cationic or anionic poly(phosphazene)s
via thermal ring-opening polymerization, nucleophilic substitution and thiol–ene click chemistry. b,c) Protonation degree (α) of diﬀerent cationic
poly(phosphazene)s (b) and of diﬀerent anionic poly(phosphazene)s (c) against pH.
and Figure 1b,c). As expected, the amine side-chain polymers
remained protonated across cytosolic and endolysosomal
pH ranges. However, the various aliphatic acid side-chain
polymers, derived from 3-mercaptopropanoic acid (3MPA),
4-mercaptobutanoic acid (4MBA), 6-mercaptohexanoic acid
(6MHA), and 8-mercaptooctanoic acid (8MOA) exhibited
buﬀering regions across the range of pH 5 to pH 8. These
titration curves were converted to line charts plotting protona-
tion degree (α) against pH (methods in Appendix, Supporting
Information). The largest shift in protonation over the critical
range of physiological pH to early endosomal pH (pH 7.4 to 6.0)
was exhibited by 6MHA-PPZ with a change in α of 61.9 ± 3.6%.
This was signiﬁcantly higher than the other anionic polymers
(Table S1, Supporting Information) and suggested that this
speciﬁc polymer should be the most advantageous in enhancing
endosomal escape of the gene carriers.
The cationic polymers were screened for polyelectrolyte com-
plex formation with plasmid DNA (pDNA) at varying N/P ra-
tios (Figure S4, Supporting Information). At N/P = 8, the di-
ameters of the complexes were all close to 80 nm and the zeta
potentials close to +40 mV. When the pDNA was added to CA-
PPZ in the presence of the various polyanions (at an 8:4 ra-
tio of amines to carboxylic acids in the mixture), the diame-
ters increased to 100 nm and the surface charges reduced to
approximately +30 mV. In addition, although the size of the
complexes did not increase signiﬁcantly with the addition of in-
creasing amounts of the polyanion 6MHA-PPZ, the total de-
rived count rate in the light scattering experiments increased
over one order of magnitude compared to the same complexes
without this anionic PPZ (Figure S4c, Supporting Informa-
tion), suggesting that more compact particulate complexes were
formed in the presence of polyanionic PPZs. This was supported
also by TEM images showing that CA-PPZ:pDNA displayed
looser structures than CA-PPZ/6MHA-PPZ:pDNA complexes
(Figure 2c,d). TEM images also corroborated the measurements
made by photon correlation spectroscopy and conﬁrmed that
CA-PPZ:pDNA complexes were smaller than CA-PPZ/6MHA-
PPZ:pDNA complexes. Polymer/pDNA complexes were isolated
from non-complexed species by high-speed centrifugation (20K
rcf, 60min) and the production yields for CA-PPZ:pDNA andCA-
PPZ/6MHA-PPZ:pDNA complexes were calculated as 85 ± 8%
and 97 ± 2%, respectively.
Agarose gel electrophoresis experiments were performed in
the absence and presence of a competing polyanion, heparin,
to test the ability of the diﬀerent polycationic PPZs for retain-
ing pDNA in the form of polyelectrolyte complexes. The data
indicated that progressive replacement of the primary amine
CA-PPZ with tertiary amine PPZ reduced the complexation ca-
pacity with pDNA (Figure 2a) as shown by increased pDNA mi-
gration from the complexes with PPZs substituted with 50%,
and particularly 100% tertiary amine groups. Complexes of CA-
PPZ:pDNA and CA-PPZ/6MHA-PPZ:pDNA were also analyzed
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Figure 2. Design of optimized PPZ:pDNA complexes. a) Gel retardation and heparin displacement tests of complexes prepared with PPZs having 100%
primary amines (P100%), P50% or P0% (8:1 N/P ratio). The remaining substitutes of each polymer correspond to tertiary amines: T0%, T50% and
T100%, respectively. b) Gel electrophoresis and heparin-displacement tests of CA-PPZ:pDNA complexes and CA-PPZ/6MHA-PPZ:pDNA complexes
(8:4:1 N/C/P ratio) at pH 7.4 and pH 5. c,d) TEM images of CA-PPZ:pDNA and CA-PPZ/6MHA-PPZ:pDNA complexes. e) Luciferase expression by
quantiﬁcation of relative luminescence unit (RLU per µg protein) obtained upon transfection of U87MG cells with CA-PPZ:pDNA complexes (8:1 N/P
ratio) and diﬀerent CA-PPZ/polyanionic PPZ:pDNA complexes (N/C/P ratio of 8:4:1, pDNA dose 1 µg cm−2) in OptiMEM (n  4). f) Cell metabolic
activity at 48 h post treatment with diﬀerent concentrations of the same complexes (n= 6). ***p-value< 0.01 via one-way ANOVA analysis with Dunnett’s
multiple comparisons test with a single pooled variance.
by agarose gel electrophoresis and then challenged with heparin
under simulated endosomal (pH 5) and standard physiological
(pH 7.4) conditions (Figure 2b). There was less pDNA release
from both CA-PPZ:pDNA and CA-PPZ/6MHA-PPZ:pDNA com-
plexes at pH 5 than at pH 7, likely due to increased polymer pro-
tonation in the more acidic environment. Also, we observed that
CA-PPZ associatedmore strongly with pDNA than themixedCA-
PPZ/6MHA-PPZ system since the latter showedmore visible gel
loading bands and partial pDNA migration at low heparin incu-
bation ratios. This eﬀect was particularly notable at pH 7.4, sug-
gesting that 6MHA-PPZmight interact with CA-PPZ and modu-
late pDNA binding, especially when the 6MHA polymer became
fully charged at its carboxylate functional groups.
Complexes based on cationic PPZs were initially tested
for their ability to transfect U87MG glioblastoma cells when
cultured as adherent monolayers. Cysteamine (primary amine)
functionalized PPZs were more eﬀective in inducing gene
expression as compared to DMAES (tertiary amine side chain)
PPZs. This was likely caused by the high pDNA-binding ef-
ﬁciency of primary amine-poly(phosphazene) at the low N/P
ratio of 8:1 (Figure 2a). In these experiments, the most favorable
compromise between transfection eﬃciency and cell viability oc-
curred at 8:1 N/P ratio with primary amine-PPZ:pDNA, and with
the polymer of higher molecular weight (Mw 36 kDa) (Figure
S5, Supporting Information). In order to provide for an endoso-
mal escape mechanism, we prepared CA-PPZ:pDNA complexes
which also contained polyanionic PPZs (3MPA-, 4MBA-, 6MHA-,
or 8MOA-PPZ) in order to introduce aliphatic carboxylate side
chains with diﬀerent ionization capacity at diﬀerent pH ranges.
Luciferase expression assays were run in U87MG monolayers
using these complexes as gene carriers, and with PEI:pDNA
complexes at the sameN/P ratios as a positive control (Figure 2e).
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Figure 3. Comparison of the intracellular traﬃcking of two selected PPZ prototypes. a) Internalization of both complexes carrying Cy5-labeled pDNA
after 4 h incubation with U87MG cells measured by Fluorescence Activated Cell Sorting. b) Intracellular distribution after 24 h of Cy5-labeled pDNA (red)
and a late-endosome/lysosome compartment marker (Lysotracker, in green) upon delivery of CA-PPZ:pDNA or CA-PPZ/6MHA-PPZ:pDNA complexes.
Intracellular distribution of Cy3-CA-PPZ (green) and Cy5-pDNA (red) after c) 24 h and d) 48 h upon delivery of CA-PPZ:pDNA or CA-PPZ/6MHA-
PPZ:pDNA complexes.
The CA-PPZ/6MHA-PPZ:pDNA complexes showed the highest
level of transgene expression combined with a minimal eﬀect on
cell metabolic activity as compared to the CA-PPZ:pDNA com-
plexes. Similar enhancements in transfection were not observed
in mixed complexes containing other polyanionic PPZs, indicat-
ing polymer-speciﬁc eﬀects that we attribute to the signiﬁcant
change in protonation of 6MHA-PPZ at endosomal pH and in de-
protonation at cytosol pH for pDNA release, especially across the
early endosomal range (pH 7.4–6.0). In addition, all polyanionic
PPZs reduced the cytotoxicity of the complexes, which was likely
due to partial shielding of the cationic charges of CA-PPZ. The
transfection enhancing eﬀect of 6MHA-PPZ was also eﬀective
with other cationic polymers with similar structure such as poly-
l-lysine (PLL), and translated to other clinically relevant glioblas-
toma models such as primary GBM1 cells[19] with remarkable
eﬃcacy (Figure S6, Supporting Information). We selected
6HMA-PPZ for nanocarrier modiﬁcation based on its unique
ability to enhance gene transfection, a characteristic probably
linked to the pKa and hydrophilic/hydrophobic balance of this
polymer. The other polyanionic polymers, 3MPA-, 4MBA- and
8MOA-PPZ, were accordingly not taken forward for the rest of
this study.
To understand the performance of CA-PPZ and CA-
PPZ/6MHA-PPZ complexes, internalization and intracellular
traﬃcking were investigated by ﬂow cytometry and confocal
microscopy. CA-PPZ:pDNA and CA-PPZ/6MHA-PPZ:pDNA
complexes were prepared with Cy5-labeled pDNA and incubated
with U87MG cells under the same transfection conditions
described previously. Flow cytometry (Figure 3a) and confocal
micrographs (Figure 3b) indicated similar levels of cellular
uptake for both prototypes. However, there were signiﬁcant
diﬀerences in the intracellular distribution of Cy5-labeled pDNA
in relation to a late endosome/lysosome marker (Lysotracker,
Invitrogen) between both prototypes. At 24 h post treatment, the
Cy5-labeled pDNA complexed with CA-PPZ/6MHA-PPZ was
more broadly distributed in the cytosol, and distal to the green-
stained lysosomes. CA-PPZ:pDNA complexes remained inside
lysosomes, resulting in yellow signals in the confocal merged
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image (Figure 3b). The analysis of ﬂuorescence intensities in
the confocal images at 24 h post treatment indicated that the
co-localization ratios (Manders’ overlap coeﬃcient as deﬁned
using the ImageJ program) of Cy5-pDNA to lysosomal markers
were 0.53 ± 0.11 in CA-PPZ complexes and 0.28 ± 0.08 in CA-
PPZ/6MHA-PPZ complexes, respectively, signiﬁcantly diﬀerent
with a p-value of 0.013 via Student’s t test. These data conﬁrmed
that the addition of 6MHA-PPZ facilitated the escape of the
complexes from the endosomal compartment. We hypothesized
that these results might be related to a capacity of 6MHA-PPZ for
destabilizing biological membranes at endosomal pH. To check
this hypothesis, hemolysis tests were performed at diﬀerent pH
values. It was found that CA-PPZ/6MHA-PPZ:pDNA complexes
had no marked hemolytic eﬀects at pH 7.4, in contrast to CA-
PPZ:pDNA complexes and the internal control (PLL complexes).
In contrast, CA-PPZ/6MHA-PPZ:pDNA complexes showed a
clear hemolytic eﬀect similar to those observed for PLL com-
plexes at pH 5.5. Therefore, these experiments conﬁrmed that
CA-PPZ/6MHA-PPZ:pDNA complexes were the only systems
tested which displayed pH-dependent membrane permeating
properties, and the data further suggested that membrane
disruption would be triggered in the endosomal compartments
(Figure S7, Supporting Information). In addition to endoso-
mal escape, intracellular distributions of the polycations and
pDNA were investigated at 24 h and 48 h post treatment for
both complexes to further understand pDNA release from
the nanocarriers. It was observed that Cy5-labeled pDNA (red
signal) was separated from Cy3-CA-PPZ/6MHA-PPZ complexes
(co-localized yellow), particularly after 48 h (Figure 3c,d). On
the other hand, the CA-PPZ complex retained its cargo pDNA
to a much higher extent, which may be the reason why the
single polycation formulations demonstrated lower transgene
expression.
Following demonstration of transgene expression in 2D
monolayers, we established 3D spheroids of U87MG cells as
simple mimics of residual tumor regions around glioblastoma-
margin areas after surgery or radiotherapy.[20] Considering the
limited penetration of excitation in microscopes and in order to
exclude complicating factors of necrosis inside the spheroids,
we selected small spheroids (diameter 250 µm) as our model.
PPZ:pDNA complexes were assayed initially to evaluate any
inherent toxicity by measuring spheroid size and metabolism
through phase-contrast images and resazurin reduction assays
(Alamar Blue), following the methods previously described[15,21]
(Figure S8, Supporting Information). Spheroids treated only
with pDNA reduced slightly in volume after 16 h in OptiMEM
media, most likely due to some nutrient depletion over this
period. Incubation of the spheroids with the CA-PPZ:pDNA
complexes at 4 µg mL−1 caused a signiﬁcant decline in volume
to 87 ± 3% of the initial value (p < 0.004) at 96 h post treatment,
whereas the analogous CA-PPZ/6MHA-PPZ:pDNA complexes
did not cause statistically signiﬁcant reduction (p = 0.132) at the
same dose. In resazurin reduction assays, themetabolic activities
of CA-PPZ/6MHA-PPZ:pDNA-treated spheroids were slightly
higher than the untreated spheroids, whereas CA-PPZ:pDNA-
treated spheroids at both DNA doses (2 µg mL−1 and 4 µg mL−1)
showed no signiﬁcant diﬀerence in metabolic activity compared
to un-treated spheroids. These experiments indicated some pos-
sible minor toxicity for CA-PPZ:pDNA at the highest dose, and,
importantly, no signs of toxicity for CA-PPZ/6MHA-PPZ:pDNA
complexes within the dose-range tested.
Further tolerability assays were performed monitoring cell
membrane damage with 7-aminoactinomycin D (7AAD) on the
previously used spheroid model. These experiments were per-
formed in parallel with transgene expression level assays of GFP
upon pDNA delivery with diﬀerent polymer complexes (Figure
4). CA-PPZ/6MHA-PPZ successfully delivered pDNA encoding
GFP as demonstrated by the percentage of GFP-positive pixels at
the regions of interest (ROIs) of spheroid images (56 ± 8% and
89± 4% for pDNA doses of 2 and 4 µgmL−1, respectively). These
GFP levels were signiﬁcantly higher than those obtained with
CA-PPZ:pDNA and PEI:pDNA either in the ﬂuorescent images
or the quantiﬁed analysis. Regarding 7AAD staining, there were
no statistically signiﬁcant diﬀerences between the polymeric
complexes at the same dose, and the levels were always far below
those of the positive control Triton X-100. In summary, the
spheroid model experiments suggested that CA-PPZ/6MHA-
PPZ:pDNA complexes achieved better transfection/toxicity
ratios than CA-PPZ:pDNA as well as the widely used PEI:pDNA
system.
To obtain further insight into the delivery system penetration
and gene transfer throughout the spheroids, ﬂuorescence
tomographic scanning was performed by ﬂuorescent light-sheet
microscopy (FLSM) (Figure 5 and tomographic-scanning videos
in Supporting Information). When the spheroids were treated
with complexes at the highest pDNA dose (4 µg mL−1), homo-
geneous GFP transfection was apparent even in the core parts of
the spheroids treated with CA-PPZ:pDNA and CA-PPZ/6MHA-
PPZ:pDNA, although GFP ﬂuorescence was most intense
with the latter system. The lower pDNA dose (2 µg mL−1) of
CA-PPZ/6MHA-PPZ:pDNA complexes still provided consistent
transfection throughout all the spheroid, whereas transfection
with CA-PPZ and PEI:pDNA complexes was clearly less (Figure
5a). These data suggested a more eﬃcient gene delivery for
CA-PPZ/6MHA-PPZ:pDNA as compared to CA-PPZ:pDNA
and the laboratory transfection standard PEI:pDNA system
in this 3D model. The results also indicated that the mixed
polycations/polyanion/nucleic acid system had a high capacity
to penetrate through a 3D tumor structures of 250 µm in
diameter. Maximum intensity projections (Figure 5b) indicated
strong ﬂuorescence throughout the spheroids transfected with
the CA-PPZ/6MHA-PPZ:pDNA complexes, supporting our
previous observations. Gene expression was also evaluated in
larger spheroids (diameter 400 µm) where we found less
transfection in the spheroid cores as compared to those tested
previously (Figure S10, Supporting Information). This could be
explained by two arguments. First, the nanocarriers were unable
to transport to the tumor core due to the extended distance.
Second, the tumor cells in the inner core of these large tumors
may have been necrotic due to excessively low oxygen tension
and thus be unable to produce GFP.
We next evaluated gene-transfer eﬃciency of the PPZ:nucleic
acid complexes in centimeter-scale xenografted tumors in vivo.
Nude mice were subcutaneously implanted with U87MG cells
on the ﬂanks, and when the tumors attained a size of 100–
150 mm3, polymeric complexes with the bi-functional plasmid
(encoding GFP and Luciferase) were injected intra-tumorally
(16 µg pDNA for each tumor). At the end of the experiment,
Adv. Therap. 2018, 1800126 C© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1800126 (9 of 15)
www.advancedsciencenews.com www.advtherap.com
Figure 4. Transfection eﬃcacy and viability of U87MG spheroids treated with polymeric complexes at two pDNA doses in OptiMEM. a) Overlay mi-
croscopy images showing GFP-expression and 7AAD-staining of U87MG-spheroids after treatments with CA-PPZ:pDNA (N/P 8:1) and CA-PPZ/6MHA-
PPZ:pDNA (N/C/P 8:4:1) at the pDNA doses of 2 µg mL−1 and 4 µg mL−1. b,c) Quantiﬁcation of GFP-ﬂuorescence and 7AAD signals from the ROIs
of spheroids in four independent experiments; spheroids treated with 2 µg mL−1 pDNA are analyzed in (b), those treated with 4 µg mL−1 in (c). (****
represents p < 0.001 and *** is p < 0.01, analyzed by a one-way ANOVA with a Dunnett’s multiple comparison test with a single pooled variance; n =
4–6).
Figure 5. 3D tomographic images of GFP-transfected spheroids taken by FLSM. a) 3D section images of CA-PPZ:pDNA and CA-PPZ/6MHA-PPZ:pDNA
treated spheroids (diameter 250 µm) at two pDNA doses of 2 and 4 µg mL−1. b) Maximum intensity projections along Z-axis (XY projection) images
of spheroids treated with diﬀerent polymer:pDNA complexes at two doses. The images were taken by FLSM. Blue corresponds to DAPI staining; green
to GFP ﬂuorescence. The ﬂuorescence images were analyzed by ImageJ and processed under the same scale of ﬂuorescence intensity.
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Figure 6. Transfection of polymeric complexes on xenograft tumors of U87MG. a) IVIS images of luciferase/GFP transfected U87MG tumors in nude
mice. b)Quantitative analysis of the ﬂuorescence in the ROI. **Statistically signiﬁcant p< 0.05 via one-way ANOVAwith aDunnett’smultiple comparison
test (n = 4).
tumors were excised, sectioned, and observed by IVIS. The data
indicated that the tumors were transfected by all the polymeric
complexes tested, with a marked increase in luminescence com-
pared to un-treated tumors (Figure 6a,b). ROI quantiﬁcation of
luciferase expression showed that CA-PPZ/6MHA-PPZ:pDNA
complexes were similar in transfection eﬃcacy to PEI-complexes
and around 1.5-fold more eﬀective than CA-PPZ:pDNA com-
plexes (Figure 6b).
Since many of the critical properties underlying the good
performance of CA-PPZ/6MHA-PPZ:pDNA nanocarriers were
based on their capacity to provide transfection in 3D environ-
ments and enhance endosomal escape, we speculated that such
advantages would translate to RNA delivery. Therefore, for a ther-
apeutic transgene, we chose a small-interfering RNA to silence
DYRK1A (siDYR), a gene implicated in the stability of EGFR
presentation and in tumor renewal.[10a,22] The polymer/siRNA
complex formulations were made using the same composition
ratio (N/C/P 8:4:1) used for the polymer/pDNA complexes
above. Primary characterization showed that substitution of
pDNA by siRNA did not induce substantial modiﬁcations
in nanocarrier characteristics (Figure S11, Supporting Infor-
mation). The DYRK1A silencing eﬃciency was measured by
qRT-PCR of DYRK1A mRNA in U87MG 2D cell cultures
(Figure 7a). CA-PPZ/6MHA-PPZ:siDYR complexes were able to
silence DYRK1A expression by 70%, while the same prototype
carrying a scrambled siRNA sequence (siCtrl) did not change
DYRK1A expression compared to non-treated cells. In addi-
tion, CA-PPZ/6MHA-PPZ:siDYR eﬃcacy was higher than the
positive control PEI:siDYR complexes, whereas CA-PPZ:siDYR
complexes did not show target inhibition. As an eﬀect of this
DYRK1A inhibition, the renewal capabilities of U87MG were
diminished by the treatment with CA-PPZ/6MHA-PPZ:siDYR
complexes, as observed in clonogenic assays evaluating the
formation of secondary spheroids (Figure 7b). This eﬀect on the
ability to form secondary spheroids was also clear in microscopy
images (Figure 7c–e) and suggested that this gene therapy
construct was capable of abrogating the tumor-initiating cell
capabilities of U87MG cells.
Based on the functional experiments in vitro, the CA-
PPZ/6MHA-PPZ complexes showed eﬃcacy in reducing sig-
niﬁcantly the renewal capability of the GBM cells. We therefore
selected this optimized formulation for further proof-of-concepts
in vivo. Complexes of CA-PPZ/6MHA-PPZ were used to deliver
siDYR (4 µg) by intratumoral injection in combination with an
intraperitoneal injection of TMZ (5 mg kg−1) once per day for 4
consecutive days, in the sameU87MG-xenograftedmousemodel
(Figure 7f, red arrows). The control group was treated the same
TMZ treatment and nanocarrier but with a scrambled siRNA
(siCtrl) as payload. In Figure 7g, tumor growth was signiﬁcantly
delayed by CA-PPZ/6MHA-PPZ:siDYR complexes from day 10
to day 14 as compared to the CA-PPZ/6MHA-PPZ:siCtrl group.
In fact, a statistical comparison of all the data from day 7 to 17 re-
vealed a strong diﬀerence between the growth of tumors treated
with siDYR complexes and those treated with siCtrl (i.e., growth
of 4.7 ± 1.4-fold for siDYR versus 8.7 ± 2.9-fold for siCtrl; p =
0.014, Student’s t test). This reduction in tumor growth rate can
be better appreciated by comparing the size of the treated tumors
and those of the controls on the same day (Figure 7g); tumors
treated with CA-PPZ/6MHA-PPZ:siDYR were around 50%
smaller than those of the control. These data underscored the
potential therapeutic superiority when combining the ﬁrst-line
treatment TMZ with CA-PPZ/6MHA-PPZ:siDYR complexes in
relation to TMZ alone.
4. Discussion
Poly(phosphazene)s have been considered as promising ma-
terials for gene delivery since they combine biodegradability
with high ﬂexibility in terms of chemical diversity. However,
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Figure 7. In vitro and in vivo silencing eﬃcacy of polymer:siDYR complexes. a) DYRK1A silencing eﬀect of diﬀerent polymer:siRNA complexes in a
2D U87MG cell model measured by qRT-PCR. b) Clonogenic ability (formation of secondary spheroids) of U87MG cells after treatment with diﬀerent
polymer:siRNA complexes. Micrographs in (c, d, e) show images of secondary spheroids after treatment with CA-PPZ/6MHA-PPZ complexing either a
therapeutic (siDYR) or a scrambled siRNA (siCtrl). f) Relative tumor volume in a U87MG xenograft tumor model treated with CA-PPZ/6MHA-PPZ:siCtrl
or CA-PPZ/6MHA-PPZ:siDYR (4 µg per tumor) and co-therapy with an intraperitoneal injection of TMZ 5 mg kg−1. This treatment was repeated for 4
consecutive days (red arrows). g) Delayed tumor growth rate (size of siDYR treated tumors divided by the size of siCtrl treated tumors) at diﬀerent time
points in the same in vivo experiment (n = 4). ** p < 0.05, analyzed by unpaired Student’s t test.
their application for gene delivery has remained relatively
unexplored because themain synthetic route for polymermodiﬁ-
cation involves nucleophilic substitution of the precursor PDCP
and is problematic for most derivatives of interest. The reason
is that functional groups often present in biomedical polymers
(i.e., amines, hydroxides, carboxylic acids, etc.) can crosslink the
precursor PDCP. Recently, PPZs have been modiﬁed with ally-
lamine and propargylamine as side groups that could be used as
click handles in thiol–ene or thiol–yne additions.[6b,23] Inspired by
those studies, we introduced vinyl groups in our systems through
the formation of a secondary polymer precursor AAPPZ, thus en-
abling furthermodiﬁcationwith functional groups of interest in a
simple step using a thiol–ene addition reaction. This method of
generating “clickable” poly(phosphazene)s for gene delivery ap-
plications has the important advantages of requiring no protec-
tion or deprotection reactions, and enables facile and rapid prepa-
ration of multiple new derivatives with primary amines or car-
boxylic acid pendent groups. The streamlined synthetic process
thus enabled structure/performance relationships to be derived
rapidly in terms of in vitro transgene expression eﬃciency.
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An important ﬁnding from the initial screening experiments
was the identiﬁcation of 6MHA-PPZ as a material with gene
delivery enhancing properties. This polymer was designed to per-
form three diﬀerent functions in the delivery system: i) improve
interpolymer complexation during the formation of the mixed
polyelectrolyte, ii) promote the release of polynucleotides from
endolysosomal compartments, and iii) reduce polycation-caused
toxicity. The capacity of anionic PPZs to enhance interpolymer
complexation was conﬁrmed by comparing CA-PPZ:pDNA (8:1
N/P ratio) and CA-PPZ/6MHA-PPZ:pDNA (8:4:1 N/C/P ratio)
complexes via dynamic light scattering and TEM imaging. Dy-
namic light scattering showed almost a one order of magnitude
increase in derived count rate when 6MHA-PPZ was added
(Figure S4c, Supporting Information). TEM images showed
that CA-PPZ/6MHA-PPZ:pDNA complexes had more compact
morphologies than CA-PPZ:pDNA complexes (Figure 2c,d).
Many standard polymers used for gene delivery are typically used
in excess to the polynucleotide. For example, while it is necessary
only to use an N/P ratio of 3 when aiming to form colloidally
stable complexes of pDNA with PEI, in practice, larger amounts
of PEI are used for improving in vitro transfection eﬃciency,
thus resulting in weakly bound or unbound PEI.[24] However,
there are concerns regarding the fate and side eﬀects of these
unbound polymers when these systems are administered in
vivo. In comparison, the dense network of the CA-PPZ/6MHA-
PPZ:pDNA complexes as shown in the TEM images suggested
that these formulations were more closely associated and thus
more likely to be delivered as intact complexes to the target cells.
A second observation regarding the function of 6MHA-PPZ
in the nanocomplexes was its capacity to increase the eﬃ-
cacy/toxicity ratio over one order of magnitude, reaching levels
similar to the laboratory transfection standard PEI:pDNA in 2D
models of U87MG cells (Figure 2e), and showing superior eﬃca-
cies in a clinically relevant glioblastoma primary cell-line (GBM1,
Figure S6, Supporting Information). Indeed, we observed that in-
troduction of all polyanionic-PPZs in the complexes reduced the
overall cellular toxicity. We infer that this reduction was partly
driven by charge neutralization, an eﬀect already reported with
other polyanions.[25] However, the other polyanionic PPZs failed
to enhance the eﬃcacy of gene delivery compared to 6MHA-PPZ
(Figure 2e). Microscopy showed that the presence of 6MHA-PPZ
in the complexes resulted in lower co-localization with the endo-
somal compartments (Figure 3b), suggesting that this improve-
ment in transfection could be related to higher capacity of these
formulations to exit the endosomal vesicles. Since this improve-
ment in transfection was speciﬁc for 6MHA-PPZ, we think it re-
sulted from the change in ionization degree of 6MHA-PPZ across
the early endosomal pH range, which was the largest among all
the polyanions we tested (Table S1, Supporting Information, and
Figure 1c). This change in ionization was most probably linked
to the capacity of 6MHA-PPZ to rupture lipid membranes in
the acid environment of the endosomes as conﬁrmed in hemol-
ysis tests (Figure S7, Supporting Information). Complexes con-
taining 6MHA-PPZ were the only ones that exhibited negligible
hemolytic eﬀects at neutral pH, but a hemolytic eﬀect compara-
ble to PLL at acidic pH. It is also of note that 6MHA-PPZ was
capable of improving cell transfection when combined with poly-
cations known to possess low endosomal escape properties, such
as PLL, although the combination with CA-PPZ was the most ef-
ﬁcient in the diﬀerent cell-lines (Figure S6, Supporting Informa-
tion), likely related to the speciﬁc optimization performed (Figure
S5a,b, Supporting Information).
Traditional 2D cell monolayer models have been widely used
for optimization of formulations, but also have been questioned
for their ability to represent physiologically relevant situations.
Three-dimensional cultures are better able to provide tissue-like
architectures (e.g., extracellular matrix, cell interactions),[26] fun-
damental tumor microenvironment traits such as nutrient and
oxygen gradients,[27] and also gene expression proﬁles similar
to those of clinical tumors.[28] To date, very few studies have in-
vestigated nucleic acid delivery in tumor spheroids despite the
fact that they are highly suited as preliminary assays before in
vivo eﬃcacy studies and that they can provide critical informa-
tion regarding tumor penetration, which is a critical barrier in
cancer drug delivery.[29] For our investigations, we used FLSM
to obtain tomographic ﬂuorescence images of GFP transfection
expression without damaging the initial spheroid structure. As
apparent in Figure 5, CA-PPZ/6MHA-PPZ:pDNA complexes ex-
hibited higher transfection in GBM spheroids as compared to
CA-PPZ:pDNA and the reference PEI:pDNA complexes; this dif-
ference was particularly marked at low pDNA doses. This im-
proved eﬃcacywas also accompanied by reduced toxicity. Overall,
these results showed high transfection eﬃcacy and tumor pene-
tration capacity for the CA-PPZ/6MHA-PPZ:pDNA formulation,
which we attribute to their partially neutralized cationic charges
at physiological pH and lower tendency to bind to the extracellu-
larmatrix in tumor spheroids. The results were also in agreement
with those from subsequent in vivo gene delivery experiments,
although direct correlation between these assays is problematic
due to inhomogeneous transfection levels observed distal of the
injection sites (Figure 6).
GBM-initiating cells are considered to be responsible for tu-
mor recurrence,[30] and therefore, their suppression is essential
for any medicine intended to provide mid- or long-term survival
beneﬁts. In the past, we have shown that controlled release
implants can deliver glioblastoma-initiating cell suppressing
molecules and provide a therapeutic beneﬁt in advanced in vivo
models.[31] Because the critical properties behind the perfor-
mance of this formulation are barriers common to both pDNA
and siRNA delivery (i.e., endosomal escape, transfection in 3D
environments), following the pilot in vivo study with pDNA,
we applied the optimized polymer prototype to deliver a siRNA
sequence with known activity against glioblastoma-initiating
cells (siDYR).[10a] As in the case of the DNA complexes, the use
of 6MHA-PPZ mixed in with the CA-PPZ complexes provided
suﬃcient ionic attraction for complexation, and as a result the
physicochemical properties of CA-PPZ/6MHA-PPZ:siRNA were
similar to CA-PPZ/6MHA-PPZ:pDNA (Figure S11, Supporting
Information). We also conﬁrmed that protein silencing observed
for cells treated with CA-PPZ/6MHA-PPZ:siDYR resulted in a
reduction in the clonogenic index in a secondary spheroid forma-
tion assay, indicating the abrogation of the “initiating cell” phe-
notype of the target cells, an eﬀect that could have major clinical
relevance in combination therapies. Sincewe expect gene therapy
to provide initial clinical beneﬁts in neuro-oncology as adjuvants
in combination with antitumoral drugs, the CA-PPZ/6MHA-
PPZ:siDYR formulation was evaluated in U87MG xenografted
mice, in a therapeutic scheme including co-delivery of the
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ﬁrst-line treatment TMZ. The experiment showed a signiﬁcant
delay in tumor progression in the treatment arm receiving TMZ
and CA-PPZ/6MHA-PPZ:siDYR versus the control arm receiv-
ing TMZ and CA-PPZ/6MHA-PPZ complexed with a scrambled
siRNA sequence (Figure 7f,g). Therefore, our results indicate
an additional therapeutic beneﬁt for the combination of CA-
PPZ/6MHA-PPZ:siDYR gene therapywith the standard pharma-
cological GBM treatment, as compared to this standard treatment
alone. Further studies will be needed to elucidate the possible
clinical impact of this combined therapy in more advanced
models and performing additional phenotypic analysis in the
tumors.
5. Conclusion
A synthetic strategy for the simple preparation of a small li-
brary of poly(phosphazene)s of interest for gene delivery was
developed based on the precursor polymer with “clickable”
sites, and further derivation by thiol–ene additions. This ap-
proach allowed us to test a variety of compounds and draw
structure/function relationships for gene delivery. Based on
the screenings, a primary amine-containing polymer (CA-PPZ)
and an anionic poly(phosphazene) analogue (6MHA-PPZ) were
selected for plasmid DNA gene delivery. These binary poly-
mer/pDNA complexes displayed signiﬁcantly higher transfec-
tion eﬃciencies than the parent polycation-only system in 2D
monolayers, 3D spheroids ofU87MG cells and in a subcutaneous
xenograft model, due to improved tumor transport and intra-
cellular traﬃcking characteristics. This optimized prototype also
showed indications of superior performance compared to labo-
ratory standard PEI complexes, particularly in 3D tumor models.
When used for RNAi therapy, CA-PPZ/6MHA-PPZ complexes
eﬃciently delivered siRNA against DYRK1A in U87MG cells, in-
ducing a signiﬁcant reduction of their self-renewal capability in
vitro and a signiﬁcant anti-tumor eﬀect in an in vivo glioblastoma
model. Overall, the data established a new versatile, biodegrad-
able polymeric gene delivery based on poly(phosphazene)s with
high capacity for gene-transfer eﬃcacy in vitro and upon in-situ
treatment in vivo.
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